Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure
The DOI matches its Crossref record, with a small difference in title or year; 61 of the 61 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We examined whether a fixed dose of both isosorbide dinitrate and hydralazine provides additional benefit in blacks with advanced heart failure, a subgroup previously noted to have a favorable response to this therapy. METHODS: A total of 1050 black patients who had New York Heart Association class III or IV heart failure with dilated ventricles were randomly assigned to receive a fixed dose of isosorbide dinitrate plus hydralazine or placebo in addition to standard therapy for heart failure. The primary end point was a composite score made up of weighted values for death from any cause, a first hospitalization for heart failure, and change in the quality of life. RESULTS: The study was terminated early owing to a significantly higher mortality rate in the placebo group than in the group given isosorbide dinitrate plus hydralazine (10.2 percent vs. 6.2 percent, P=0.02). The mean primary composite score was significantly better in the group given isosorbide dinitrate plus hydralazine than in the placebo group (-0.1+/-1.9 vs. -0.5+/-2.0, P=0.01; range of possible values, -6 to +2), as were its individual components (43 percent reduction in the rate of death from any cause [hazard ratio, 0.57; P=0.01] 33 percent relative reduction in the rate of first hospitalization for heart failure [16.4 percent vs. 22.4 percent, P=0.001], and an improvement in the quality of life [change in score, -5.6+/-20.6 vs. -2.7+/-21.2, with lower scores indicating better quality of life; P=0.02; range of possible values, 0 to 105]). CONCLUSIONS: The addition of a fixed dose of isosorbide dinitrate plus hydralazine to standard therapy for heart failure including neurohormonal blockers is efficacious and increases survival among black patients with advanced heart failure.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The primary outcome was a weighted score, but individual components of the outcome showed a difference favouring H-ISDN for all-cause mortality, first HHF, and change in quality of life score.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [79]
In the citing paper
“Digoxin may reduce the risk of HF hospitalization in patients with HFrEF treated with ACE-Is, irrespective of diabetes status.519”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [519]
Citations
Cites
Pfeffer, M. A., Braunwald, E., Moyé, L. A., Basta, L., Brown, E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271001 · Cited by 5,911
Effects of Enalapril on Mortality in Severe Congestive Heart Failure
The Consensus Trial Study Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162301 · Cited by 5,121
Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress
Cai, H., & Harrison, D. G. (2000) · Circulation Research · doi:10.1161/01.res.87.10.840 · Cited by 3,839
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Self-citationEffect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442201 · Cited by 3,093
Cohn, J. N., Johnson, G., Ziesche, S., Cobb, F., Francis, G., Tristani, F., Smith, R., Dunkman, W. B., Loeb, H., Wong, M., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250502 · Cited by 2,833
Self-citationSuperoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor
Gryglewski, R. J., Palmer, R. M. J., & Moncada, S. (1986) · Nature · doi:10.1038/320454a0 · Cited by 2,400
Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure
Cohn, J. N., Archibald, D. G., Ziesche, S., Franciosa, J. A., Harston, W. E., Tristani, F. E., Dunkman, W. B., Jacobs, W., Francis, G. S., Flohr, K. H., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606123142404 · Cited by 2,400
Self-citationEffect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., & Fowler, M. B. (2001) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00477-9 · Cited by 1,661
Cited by
Items 101–200 of 1,001
Advances In The Prevention And Treatment Of Cardiovascular Disease
Weisfeldt, M. L., & Zieman, S. J. (2007) · Health Affairs · doi:10.1377/hlthaff.26.1.25 · Cited by 250
Kapil, V., Khambata, R. S., Jones, D. A., Rathod, K., Primus, C., Massimo, G., Fukuto, J. M., & Ahluwalia, A. (2020) · Pharmacological Reviews · doi:10.1124/pr.120.019240 · Cited by 248
“…organic nitrates provide an efficacious treatment option in the setting of acute HF and have shown some benefit in chronic HF (Cohn et al., 1986; Taylor et al., 2004), they have proven difficult to use as a long-term option because of the rapid development of tolerance, reflex tachycardia, and…”
BackgroundRotariu, D., Babes, E. E., Tit, D. M., Moisi, M., Bustea, C., Stoicescu, M., Radu, A.-F., Vesa, C. M., Behl, T., Bungau, A. F., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113238 · Cited by 225
McDowell, S. E., Coleman, J. J., & Ferner, R. E. (2006) · BMJ · doi:10.1136/bmj.38803.528113.55 · Cited by 248
Chronic Heart Failure: Contemporary Diagnosis and Management
Ramani, G. V., Uber, P. A., & Mehra, M. R. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0494 · Cited by 236
Reverse remodeling in heart failure—mechanisms and therapeutic opportunities
Koitabashi, N., & Kass, D. A. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.172 · Cited by 236
“However, it reappeared 13 years later in the form of a combination pill (containing the same components) in the African-American Heart Failure Trial”
BackgroundPharmacogenetics and the concept of individualized medicine
Shastry, B. S. (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500338 · Cited by 236
Pharmacogenetics and Pharmacogenomics: Development, Science, and Translation
Weinshilboum, R. M., & Wang, L. (2006) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.6.080604.162315 · Cited by 231
Potential impact of optimal implementation of evidence-based heart failure therapies on mortality
Fonarow, G. C., Yancy, C. W., Hernandez, A. F., Peterson, E. D., Spertus, J. A., & Heidenreich, P. A. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.01.027 · Cited by 230
Self-citationBöhm, M., Young, R., Jhund, P. S., Solomon, S. D., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Swedberg, K., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehw570 · Cited by 219
Zannad, F., Garcia, A. A., Anker, S. D., Armstrong, P. W., Calvo, G., Cleland, J. G. F., Cohn, J. N., Dickstein, K., Domanski, M. J., Ekman, I., et al. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hft095 · Cited by 231
Self-citationDiabetes, left ventricular systolic dysfunction, and chronic heart failure
MacDonald, M. R., Petrie, M. C., Hawkins, N. M., Petrie, J. R., Fisher, M., McKelvie, R., Aguilar, D., Krum, H., & McMurray, J. J. V. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn156 · Cited by 227
“renal dysfunction, may indirectly exclude individuals with DM).(8,9)”
BackgroundInfluentialSodium Nitroprusside for Advanced Low-Output Heart Failure
Mullens, W., Abrahams, Z., Francis, G. S., Skouri, H. N., Starling, R. C., Young, J. B., Taylor, D. O., & Tang, W. H. W. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.02.083 · Cited by 219
Cardiovascular Health Disparities
Davis, A. M., Vinci, L. M., Okwuosa, T. M., Chase, A. R., & Huang, E. S. (2007) · Medical Care Research and Review · doi:10.1177/1077558707305416 · Cited by 218
Racial and ethnic disparities in heart failure: current state and future directions
Lewsey, S. C., & Breathett, K. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000855 · Cited by 209
2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults
Jessup, M., Abraham, W. T., Casey, D. E., Feldman, A. M., Francis, G. S., Ganiats, T. G., Konstam, M. A., Mancini, D. M., Rahko, P. S., Silver, M. A., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.11.009 · Cited by 215
Self-citationβ-Adrenergic stimulation and myocardial function in the failing heart
El-Armouche, A., & Eschenhagen, T. (2009) · Heart Failure Reviews · doi:10.1007/s10741-008-9132-8 · Cited by 202
“For example, a study in African Americans showed that homozygous carriers of the (rare) combination of b1-AR Arg389 and a2CDel variants were 10-fold overrepresented in a cohort of patients with heart failure compared with a control population (*20 vs. 2%, [132]).”
BackgroundInfluentialComorbidity of atrial fibrillation and heart failure
Ling, L.-H., Kistler, P. M., Kalman, J. M., Schilling, R. J., & Hunter, R. J. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.191 · Cited by 213
Mapping by admixture linkage disequilibrium: advances, limitations and guidelines
Smith, M. W., & O'Brien, S. J. (2005) · Nature Reviews Genetics · doi:10.1038/nrg1657 · Cited by 221
The Role of Nitroglycerin and Other Nitrogen Oxides in Cardiovascular Therapeutics
Divakaran, S., & Loscalzo, J. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.09.1064 · Cited by 204
“Given the striking results of the African-American Heart Failure Trial however, the combination of hydralazine and isosorbide dinitrate, together with angiotensinconverting enzyme inhibitors, beta-blockers, and aldosterone antagonists, is recommended by current guidelines for African-Americans who require further bloo…”
McKelvie, R. S., Moe, G. W., Ezekowitz, J. A., Heckman, G. A., Costigan, J., Ducharme, A., Estrella-Holder, E., Giannetti, N., Grzeslo, A., Harkness, K., et al. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.10.007 · Cited by 208
“The African-American Heart Failure Trial (A-HeFT) showed that adding a fixed-dose combination of isosorbide dinitrate plus hydralazine to a contemporary standard therapy reduced mortality, first hospitalization for HF, and improved quality of life among African-American patients with HF-REF.(80) A recent study in pati…”
BackgroundInfluentialHeart failure in sub-Saharan Africa: A contemporaneous systematic review and meta-analysis
Agbor, V. N., Essouma, M., Ntusi, N. A. B., Nyaga, U. F., Bigna, J. J., & Noubiap, J. J. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.12.048 · Cited by 200
Chiang, C.-E., Wang, T.-D., Ueng, K.-C., Lin, T.-H., Yeh, H.-I., Chen, C.-Y., Wu, Y.-J., Tsai, W.-C., Chao, T.-H., Chen, C.-H., et al. (2015) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2014.11.005 · Cited by 199
“However, hydralazine in combination with isosorbide dinitrate, is effective in AfricanAmericans who have symptomatic heart failure.(359) Because of the severity of adverse effects with minoxidil, its usage is limited to persons with severe hypertension unresponsive to other treatment.”
BackgroundHarkness, A., Ring, L., Augustine, D. X., Oxborough, D., Robinson, S., & Sharma, V. (2020) · Echo Research & Practice · doi:10.1530/erp-19-0050 · Cited by 191
“When the LVEF is below 50%, there remains a reasonable body of evidence that therapeutic agents may be of value in improving survival (44, 45, 46).”
Mason, R. P., Kalinowski, L., Jacob, R. F., Jacoby, A. M., & Malinski, T. (2005) · Circulation · doi:10.1161/circulationaha.105.556233 · Cited by 194
Lee, C. R., North, K. E., Bray, M. S., Fornage, M., Seubert, J. M., Newman, J. W., Hammock, B. D., Couper, D. J., Heiss, G., & Zeldin, D. C. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl085 · Cited by 193
“Future studies evaluating the vascular effects of EPHX2 in Caucasians and African-Americans appear warranted, particularly because racial differences in endothelial-targeted therapies have been reported in other cardiovascular disease populations (31).”
Effects of Beta-Blocker Withdrawal in Acute Decompensated Heart Failure
Prins, K. W., Neill, J. M., Tyler, J. O., Eckman, P. M., & Duval, S. (2015) · JACC: Heart Failure · doi:10.1016/j.jchf.2015.03.008 · Cited by 190
“Despite major strides in chronic heart failure marked by significant mortality reductions of 33% to 35% with beta-blockers (2–4), 16% to 27% with angiotensin-converting enzyme inhibitors (5,6), 43% with hydralazine/isosorbide dinitrate (7), and 24% to 30% with aldosterone antagonists (8,9), outcomes have changed littl…”
BackgroundHeart Failure Care in the Outpatient Cardiology Practice Setting: Findings From IMPROVE HF
Fonarow, G. C., Yancy, C. W., Albert, N. M., Curtis, A. B., Stough, W. G., Gheorghiade, M., Heywood, J. T., McBride, M. L., Mehra, M. R., O'Connor, C. M., et al. (2008) · Circulation: Heart Failure · doi:10.1161/circheartfailure.108.772228 · Cited by 187
Self-citationDiastolic heart failure in anaesthesia and critical care
Pirracchio, R., Cholley, B., De Hert, S., Solal, A. C., & Mebazaa, A. (2007) · British Journal of Anaesthesia · doi:10.1093/bja/aem098 · Cited by 182
Under-representation of minority ethnic groups in research--call for action
Redwood, S., & Gill, P. S. (2013) · British Journal of General Practice · doi:10.3399/bjgp13x668456 · Cited by 182
Rosendorff, C., Lackland, D. T., Allison, M., Aronow, W. S., Black, H. R., Blumenthal, R. S., Cannon, C. P., de Lemos, J. A., Elliott, W. J., Findeiss, L., et al. (2015) · Hypertension · doi:10.1161/hyp.0000000000000018 · Cited by 176
Leitlinien zur Therapie der chronischen Herzinsuffizienz
Hoppe, U. C., Böhm, M., Dietz, R., Hanrath, P., Kroemer, H. K., Osterspey, A., Schmaltz, A. A., & Erdmann, E. (2005) · Zeitschrift für Kardiologie · doi:10.1007/s00392-005-0268-4 · Cited by 169
“Bei Schwarzafrikanern im NYHAStadium III–IV reduzierte die additive Gabe von Hydralazin (Zieldosis 225 mg/Tag) und Isosorbiddinitrat (Zieldosis 120 mg/Tag) zu einer Standardtherapie mit ACE-Hemmer und -Blocker signifikant die Gesamtsterblichkeit [84].”
BackgroundGolwala, H., Pandey, A., Ju, C., Butler, J., Yancy, C., Bhatt, D. L., Hernandez, A. F., & Fonarow, G. C. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.06.1089 · Cited by 168
Self-citationMedical Therapy for Heart Failure Caused by Ischemic Heart Disease
Elgendy, I. Y., Mahtta, D., & Pepine, C. J. (2019) · Circulation Research · doi:10.1161/circresaha.118.313568 · Cited by 176
Daiber, A., & Münzel, T. (2015) · Antioxidants & Redox Signaling · doi:10.1089/ars.2015.6376 · Cited by 167
“In addition, the double-blind, randomized African American Heart Failure Trial (A-HeFT) demonstrated that the combination of ISDN and hydralazine was markedly effective in improving the composite endpoint of the trial, which included death from any cause, a first hospitalization for heart failure, and quality of life…”
BackgroundEvolving Applications for Patient-Centered Health Status Measures
Spertus, J. A. (2008) · Circulation · doi:10.1161/circulationaha.107.747568 · Cited by 171
Population differences in microRNA expression and biological implications
Huang, R. S., Gamazon, E. R., Ziliak, D., Wen, Y., Im, H. K., Zhang, W., Wing, C., Duan, S., Bleibel, W. K., Cox, N. J., et al. (2011) · RNA Biology · doi:10.4161/rna.8.4.16029 · Cited by 171
Daiber, A., & Chlopicki, S. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.02.026 · Cited by 166
III Diretriz Brasileira de Insuficiência Cardíaca Crônica
Bocchi, E. A., Marcondes‐Braga, F. G., Ayub‐Ferreira, S. M., Rohde, L. E. P., Junior, W. A. D. O., Almeida, D. R., Moreira, M. D. C. V., Bestetti, R. B., Bordignon, S., Azevedo, C., et al. (2009) · Americanae (AECID Library) · doi:10.1590/s0066-782x2009002000001 · Cited by 170
Nitric Oxide Synthases in Heart Failure
Carnicer, R., Crabtree, M. J., Sivakumaran, V., Casadei, B., & Kass, D. A. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4824 · Cited by 163
“Nonetheless, recent evidence of the benefits of this drug class combined with hydralazline in the African-American sub-population of heart failure patients has revived interest (221).”
Atualização de Tópicos Emergentes da Diretriz Brasileira de Insuficiência Cardíaca – 2021
Marcondes‐Braga, F. G., Moura, L. Z., Issa, V. S., Vieira, J. L., Rohde, L. E. P., Simões, M. V., Fernandes-Silva, M. M., Rassi, S., Martins, S. M., de Albuquerque, D. C., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210367 · Cited by 245
Packer, M., & McMurray, J. J. V. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2149 · Cited by 160
Krum, H., & Abraham, W. T. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60236-1 · Cited by 159
Inflammation in Human Heart Failure: Major Mediators and Therapeutic Targets
Reina‐Couto, M., Pereira‐Terra, P., Quelhas‐Santos, J., Silva-Pereira, C., Albino‐Teixeira, A., & Sousa, T. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.746494 · Cited by 180
Nitroso–Redox Interactions in the Cardiovascular System
Zimmet, J. M., & Hare, J. M. (2006) · Circulation · doi:10.1161/circulationaha.105.605519 · Cited by 169
Nitroso–Redox Balance in the Cardiovascular System
Hare, J. M. (2004) · New England Journal of Medicine · doi:10.1056/nejme048269 · Cited by 162
Perioperative Management of Chronic Heart Failure
Groban, L., & Butterworth, J. (2006) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000226099.60493.d9 · Cited by 162
“5 up to 225 mg) in 3 divided doses versus placebo (n 532), added to standard background RAS blockade (31).”
BackgroundTherapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis
Herman, A. G., & Moncada, S. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi333 · Cited by 149
“2% mortality in the placebo and ISDNþ hydralazine groups, respectively) among 1050 black patients with advanced heart failure (NYHA Class III or IV).(126) In contrast, in the ISIS-4 (Fourth International Study of Infarct Survival) placebo-controlled study, there was no significant reduction in 5 week mortality in pati…”
Free radical biology of the cardiovascular system
Chen, A. F., Chen, D.-D., Daiber, A., Faraci, F. M., Li, H., Rembold, C. M., & Laher, I. (2012) · Clinical Science · doi:10.1042/cs20110562 · Cited by 152
Lim, S. L., Lam, C. S. P., Segers, V. F. M., Brutsaert, D. L., & De Keulenaer, G. W. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv132 · Cited by 152
Wilson, S. R., Givertz, M. M., Stewart, G. C., & Mudge, G. H. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.06.035 · Cited by 165
ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly
Aronow, W. S., Fleg, J. L., Pepine, C. J., Artinian, N. T., Bakris, G. L., Brown, A. S., Ferdinand, K. C., Forciea, M. A., Frishman, W. H., Jaigobin, C. S., et al. (2011) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2011.06.001 · Cited by 172
Self-citationAssociations of Gender and Etiology With Outcomes in Heart Failure With Systolic Dysfunction
Frazier‐Mills, C. G., Alexander, K. P., Newby, L. K., Anderson, S., Iverson, E. R., Packer, M., Cohn, J. N., Goldstein, S., & Douglas, P. S. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.11.041 · Cited by 167
Self-citationBloche, M. G. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048271 · Cited by 150
The association between blood pressure and mortality in patients with heart failure
Lee, T. T., Chen, J., Cohen, D. J., & Tsao, L. (2005) · American Heart Journal · doi:10.1016/j.ahj.2005.03.009 · Cited by 146
Hacking, I. (2005) · Daedalus · doi:10.1162/0011526053124460 · Cited by 135
Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O. D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.11.027 · Cited by 177
Rethinking Composite End Points in Clinical Trials: Insights From Patients and Trialists
Stolker, J. M., Spertus, J. A., Cohen, D. J., Jones, P. G., Jain, K. K., Bamberger, E., Lonergan, B. B., & Chan, P. S. (2014) · Circulation · doi:10.1161/circulationaha.113.006588 · Cited by 143
“28 Trialists 164 40 (28-48) 25 (18-28) 21 (16-28) 8 (4-12) 5 (4-8) 0.”
de Wit, M., Gennings, C., Jenvey, W. I., & Epstein, S. K. (2008) · Critical Care · doi:10.1186/cc6908 · Cited by 139
Bozkurt, B., & Khalaf, S. Z. (2017) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-13-4-216 · Cited by 157
Identifying Patients Hospitalized With Heart Failure at Risk for Unfavorable Future Quality of Life
Allen, L. A., Gheorghiade, M., Reid, K. J., Dunlay, S. M., Chan, P. S., Hauptman, P. J., Zannad, F., Konstam, M. A., & Spertus, J. A. (2011) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.110.958009 · Cited by 136
Adherence to Federal Guidelines for Reporting of Sex and Race/Ethnicity in Clinical Trials
Geller, S. E., Adams, M. G., & Carnes, M. (2006) · Journal of Women's Health · doi:10.1089/jwh.2006.15.1123 · Cited by 134
“Analysis by sex provided 5 (14) 0 0 1 (50) 6 (13) or sex included in model Did not analyze by sex but 8 (22) 1 (14) 0 0 9 (20) provided an explanation Did not include sex in 23 (64) 6 (86) 1 (100) 1 (50) 31 (67) analysis or did not provide an explanation or both Total 36 (100) 7 (100) 1 (100) 2 (100) 46 (100)”
Treatment of Hypertension in Patients With Coronary Artery Disease
Rosendorff, C., Lackland, D. T., Allison, M., Aronow, W. S., Black, H. R., Blumenthal, R. S., Cannon, C. P., de Lemos, J. A., Elliott, W. J., Findeiss, L., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.02.038 · Cited by 155
Common Variants in HSPB7 and FRMD4B Associated With Advanced Heart Failure
Cappola, T. P., Li, M., He, J., Ky, B., Gilmore, J., Qu, L., Keating, B., Reilly, M., Kim, C. E., Glessner, J., et al. (2010) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.109.898395 · Cited by 135
Clinical Pharmacology of Antihypertensive Therapy for the Treatment of Hypertension in CKD
Sinha, A. D., & Agarwal, R. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04330418 · Cited by 135
Lakdawala, N. K., Winterfield, J. R., & Funke, B. (2012) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.111.962050 · Cited by 145
Race and ancestry in biomedical research: exploring the challenges
Caulfield, T., Fullerton, S. M., Ali-Khan, S. E., Arbour, L., Burchard, E. G., Cooper, R. S., Hardy, B.-J., Harry, S., Hyde-Lay, R., Kahn, J., et al. (2009) · Genome Medicine · doi:10.1186/gm8 · Cited by 130
Chronic Heart Failure: Current Evidence, Challenges to Therapy, and Future Directions
Morrissey, R. P., Czer, L. S. C., & Shah, P. K. (2011) · American Journal of Cardiovascular Drugs · doi:10.2165/11592090-000000000-00000 · Cited by 137
Once Daily Therapy With Isosorbide-5-Mononitrate Causes Endothelial Dysfunction in Humans
Thomas, G. R., DiFabio, J. M., Gori, T., & Parker, J. D. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.10.074 · Cited by 142
Enrichment of Clinical Study Populations
Temple, R. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.233 · Cited by 131
Key Issues in End Point Selection for Heart Failure Trials: Composite End Points
Neaton, J. D., Gray, G. W., Zuckerman, B. D., & Konstam, M. A. (2005) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2005.08.350 · Cited by 138
The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes
Dzau, V. J., Antman, E. M., Black, H. R., Hayes, D. L., Manson, J. E., Plutzky, J., Popma, J. J., & Stevenson, W. G. (2006) · Circulation · doi:10.1161/circulationaha.106.655761 · Cited by 158
McMurray, J., Cohen-Solal, A., Dietz, R., Eichhorn, E., Erhardt, L., Hobbs, F. D. R., Krum, H., Maggioni, A., McKelvie, R. S., Piña, I. L., et al. (2005) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2005.07.002 · Cited by 131
Wexler, R., Elton, T. S., Pleister, A. P., & Feldman, D. S. (2009) · PubMed · Cited by 209
Heart Failure in Sub-Saharan Africa
Bloomfield, G. S., Barasa, F. A., Doll, J. A., & Velazquez, E. J. (2013) · Current Cardiology Reviews · doi:10.2174/1573403x11309020008 · Cited by 139
Postinfarct Left Ventricular Remodelling: A Prevailing Cause of Heart Failure
Galli, A., & Lombardi, F. (2016) · Cardiology Research and Practice · doi:10.1155/2016/2579832 · Cited by 137
Psoriasis in skin of color: epidemiology, genetics, clinical presentation, and treatment nuances.
Alexis, A. F., & Blackcloud, P. (2014) · PubMed Central · Cited by 125
Creatine Kinase Activity Is Associated With Blood Pressure
Brewster, L. M., Mairuhu, G., Bindraban, N. R., Koopmans, R. P., Clark, J. F., & van Montfrans, G. A. (2006) · Circulation · doi:10.1161/circulationaha.105.584490 · Cited by 135
Epidemiology, Pathophysiology, Prognosis, and Treatment of Systolic and Diastolic Heart Failure
Aronow, W. S. (2006) · Cardiology in Review · doi:10.1097/01.crd.0000175289.87583.e5 · Cited by 138
Sex differences in heart failure
Eisenberg, E., Palo, K. E. D., & Piña, I. L. (2018) · Clinical Cardiology · doi:10.1002/clc.22917 · Cited by 132
“Both men and women with HFrEF who self-identify as African American with New York Heart Association class III to IV symptoms benefited from combination hydralazine and isosorbide dinitrate when added to ACE inhibitor/ARB and β-blocker therapy as evidenced by A-HeFT (African-American Heart Failure Trial).(54) However,…”
MethodChanges of Natriuretic Peptides Predict Hospital Admissions in Patients With Chronic Heart Failure
Savarese, G., Musella, F., D’Amore, C., Vassallo, E., Losco, T., Gambardella, F., Cecere, M., Petraglia, L., Pagano, G., Fimiani, L., et al. (2014) · JACC Heart Failure · doi:10.1016/j.jchf.2013.11.007 · Cited by 139
Changing How Race Is Portrayed in Medical Education: Recommendations From Medical Students
Nieblas-Bedolla, E., Christophers, B., Nkinsi, N. T., Schumann, P. D., & Stein, E. (2020) · Academic Medicine · doi:10.1097/acm.0000000000003496 · Cited by 113
Amir, E., Šeruga, B., Kwong, R., Tannock, I. F., & Ocaña, A. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.10.028 · Cited by 133
S-nitrosylation: integrator of cardiovascular performance and oxygen delivery
Haldar, S. M., & Stamler, J. S. (2013) · Journal of Clinical Investigation · doi:10.1172/jci62854 · Cited by 127
“…that NO donors (e.g., isosorbide dini-trate, nitroglycerin) have beneficial effects in patients with heart failure and ischemic heart disease (115–118), these therapies may function, in part, via modulating S -nitrosylation of key myocardial proteins (e.g., RYR2, HIF-1 α , and β 2 -AR…”
(2022) · PubMed Central · doi:10.6515/acs.202205_38(3).20220321a · Cited by 117
Current trends in heart failure readmission rates: analysis of medicare data
Aranda, J. M., Johnson, J. W., & Conti, J. B. (2009) · Clinical Cardiology · doi:10.1002/clc.20453 · Cited by 116
Venous Tone and Stressed Blood Volume in Heart Failure
Fudim, M., Kaye, D. M., Borlaug, B. A., Shah, S. J., Rich, S., Kapur, N. K., Costanzo, M. R., Brener, M. I., Sunagawa, K., & Burkhoff, D. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.02.050 · Cited by 114
Westerman, S. B., & WENGER, N. K. (2016) · Clinical Science · doi:10.1042/cs20150586 · Cited by 121
MANAGEMENT OF END STAGE HEART FAILURE
Friedrich, E. B., & Böhm, M. (2007) · Heart · doi:10.1136/hrt.2006.098814 · Cited by 130
Taylor, A. L., Ziesche, S., Yancy, C. W., Carson, P., Ferdinand, K., Taylor, M., Adams, K., Olukotun, A. Y., Ofili, E., Tam, S. W., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.644013 · Cited by 114
Self-citationImpact of Systemic Venous Congestion in Heart Failure
Dupont, M., Müllens, W., & Tang, W. H. W. (2011) · Current Heart Failure Reports · doi:10.1007/s11897-011-0071-7 · Cited by 122
“In the contemporary management with neurohormonal antagonists, add-on combination therapy with hydralazine and isosorbide dinitrate still provides incremental benefit in subsets of patients with significant symptoms or advanced disease states [21, 22].”
Methodde Diagnóstico, G. D. T., & de Cardiología, T. D. L. I. C. C. D. L. S. E. (2005) · Revista Española de Cardiología · doi:10.1157/13078554 · Cited by 125
Embracing Genetic Diversity to Improve Black Health
Oni-Orisan, A., Mavura, Y., Banda, Y., Thornton, T. A., & Sebro, R. (2021) · New England Journal of Medicine · doi:10.1056/nejmms2031080 · Cited by 110
Howlett, J. G., McKelvie, R. S., Costigan, J., Ducharme, A., Estrella-Holder, E., Ezekowitz, J. A., Giannetti, N., Haddad, H. A., Heckman, G. A., Herd, A. M., et al. (2010) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(10)70367-6 · Cited by 128
Daiber, A., Oelze, M. W., Coldewey, M., Kaiser, K., Huth, C., Schildknecht, S., Bachschmid, M. M., Nazirisadeh, Y., Ullrich, V., Mülsch, A., et al. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.10.106 · Cited by 115
The Management of Hypertension in African Americans
Ferdinand, K. C., & Armani, A. M. (2007) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/hpc.0b013e318053da59 · Cited by 112
Self-citationFranks, P. J., Muennig, P. A., Lubetkin, E. I., & Jia, H. (2005) · Social Science & Medicine · doi:10.1016/j.socscimed.2005.10.035 · Cited by 124
“The recent release of a drug combination (nitrate/ hydralazine) to treat heart failure in AfricanAmericans has fueled this controversy (Taylor et al., 2004).”
BackgroundThe Role of Race and Genetics in Health Disparities Research
Fine, M. J., Ibrahim, S. A., & Thomas, S. B. (2005) · American Journal of Public Health · doi:10.2105/ajph.2005.076588 · Cited by 111
How can we cure a heart “in flame”? A translational view on inflammation in heart failure
Hofmann, U., & Frantz, S. (2013) · Basic Research in Cardiology · doi:10.1007/s00395-013-0356-y · Cited by 118
“Isosorbide dinitrate ? hydralazine [135] 1,050 24 % III–IV Mixed Improved composite endpoint in African– Americans.”
BackgroundBiDil for Heart Failure in Black Patients: The U.S. Food and Drug Administration Perspective
Temple, R., & Stockbridge, N. L. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-1-200701020-00010 · Cited by 109
“The principal trial of BiDil was the African American Heart Failure Trial (A-HeFT) (7), a randomized comparison of hydralazine hydrochloride–isosorbide dinitrate and placebo in self-identified black patients with New York Heart Association (NYHA) class III or IV (mostly III) heart failure.”
Background
Metadata
- Authors
- Taylor, A. L., Ziesche, S., Yancy, C., Carson, P., D'Agostino, R., Ferdinand, K., Taylor, M., Adams, K., Sabolinski, M., Worcel, M., & Cohn, J. N.
- Affiliations
- University of Minnesota (US)
- United States Department of Veterans Affairs (US)
- The University of Texas Southwestern Medical Center (US)
- Veterans Health Administration (US)
- Xavier University of Louisiana (US)
- Association of Black Cardiologists (US)
- University of North Carolina at Chapel Hill (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-11-11
- Volume
- 351
- Issue
- 20
- Pages
- 2049-2057
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2140023412
- Cited by
- 1,773
- References
- 61
- Citations by year
- 2026: 28 · 2025: 30 · 2024: 43 · 2023: 67 · 2022: 68 · 2021: 70 · 2020: 76 · 2019: 53 · 2018: 58 · 2017: 90 · 2016: 78 · 2015: 79 · 2014: 76 · 2013: 78 · 2012: 97
- FWCI
- 84.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- isosorbide dinitrate, hydralazine, advanced heart failure, Black patients, fixed-dose combination, mortality, heart failure hospitalization, quality of life, dilated ventricles
- MeSH terms
- Adult, Aged, Double-Blind Method, Drug Combinations, Drug Therapy, Combination, Female, Heart Failure, Humans, Hydralazine, Isosorbide Dinitrate, Male, Middle Aged, Quality of Life, Vasodilator Agents, Survival Analysis, Treatment Outcome, Nitric Oxide Donors, Black People
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.